NCT05367635 - A Study of SKB315 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

206

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

February 28, 2026

Conditions

Advanced Solid Tumors

Interventions

DRUG

SKB315 for injection

SKB315 for injection is an Antibody Drug Conjugates (ADC) drug targeting Claudin18.2. The strength of SKB315 is 200 mg/vial.

Trial Locations (1)

RECRUITING

Tianjin Medical University Cancer Institute & Hospital, Tianjin

All Listed Sponsors

lead

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

INDUSTRY